This document describes how the Agilent 2100 Bioanalyzer replaces gel electrophoresis in prostate cancer research.
This document details a study utilizing the Agilent 2100 Bioanalyzer to detect telomerase in expressed prostatic secretions for prostate cancer evaluation. The authors compare this microfluidics-based system against traditional agarose gel electrophoresis, highlighting the Bioanalyzer's ability to replace the gel step with a more rapid and reliable detection method.
| Analysis Time | less than one hour |
|---|---|
| Chip Capacity | 12 samples |
The Agilent 2100 Bioanalyzer replaces the gel electrophoresis step with a more rapid and reliable detection system.
The system replaces gel electrophoresis to quickly detect the presence of telomerase in expressed prostatic secretions for prostate cancer evaluation.
The chip holds up to 12 samples for processing, and all 12 can be analyzed in less than one hour.